Ingmar Hoerr, PhD, MBA, Chairman
founded CureVac in 2000 together with Florian von der Mülbe and other colleagues in Tübingen and was CEO of CureVac for 18 years...
founded CureVac in 2000 together with Florian von der Mülbe and other colleagues in Tübingen and was CEO of CureVac for 18 years. His entrepreneurship was motivated by a surprising discovery during his doctoral research. Experiments conducted for this research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed. From this key discovery, the founders built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs.
Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the High Level Group of Innovators in developing a European Innovation Council and is juror of the founder prize Weconomy.